MelaPro Dx        

The MelaPro Dx™ test, patent pending, was developed in collaboration with Dr. Rossitza Lazova, formerly of Yale University, beginning in early 2014. The goal of this research partnership was to develop an ancillary diagnostic test that evaluates a wide variety of cutaneous melanocytic lesion subtypes commonly reviewed by dermatopathologists on a daily basis. MelaPro Dx is intended to help physicians reduce the number of indeterminant diagnoses resulting from routine histopathological reviews of melanocytic lesions and provide the following additional benefits as compared to currently available tests:

  • Improved sensitivity and specificity
  • Objective classification results
  • Reduced specimen material requirements
  • Quicker results turnaround
  • Improved healthcare savings


Rossitza Lazova, MD

Director of Dermatopathology
California Skin Institute

Dr. Rossitza Lazova completed a residency in Anatomic and Clinical Pathology at the University of Rochester Medical Center in Rochester, New York and trained in Dermatopathology with Dr. A. Bernard Ackerman at the Institute for Dermatopathology at Thomas Jefferson Medical College in Philadelphia. After completion of her fellowship, she started her academic career at the Department of Dermatology, Yale University School of Medicine, where she spent almost 20 years.

Dr. Lazova is well known worldwide in the field of Dermatopathology. She has published numerous articles in peer-reviewed journals and chapters in books. She is also a co-author of two textbooks and the latest WHO Classification of Skin Tumours, 4th Ed. Dr. Lazova’s main interest is in melanocytic lesions and particularly Spitzoid neoplasms.

Dr. Lazova has held many leadership positions, including a member of the Board of Directors of the American Society of Dermatopathology, chair of the Membership Committee and chair of the Mentorship Committee of the ASDP. She is the past Vice President of the International Society of Dermatopathology and current chair of the Travel Award Committee and member of the Executive Committee of the ISDP.

Dr. Lazova has taught many courses and directed numerous sessions at national and international meetings in the USA and throughout the world. She is on the editorial board of many prestigious journals. Dr. Lazova has been a Director of the Dermatopathology Fellowship at Yale University for fourteen years, where she has trained many fellows and residents. She has developed an international program and has mentored over fifty physicians from twenty-three countries and four continents.


The EsophaPro Px™ test, patent pending, is being developed in collaboration with Dr. Steven Lin at the MD Anderson Cancer Center. The goal of this research partnership is to develop an ancillary prognostic test that provides physicians with predictive knowledge about whether an esophageal cancer patient is likely to respond to chemoradiotherapy. EsohpaPro Px is intended to help physicians reduce the number of unnecessary surgeries (i.e., esophagectomies) and provide the following additional benefits for a physician community that lacks an effective test:

  • Accurate and objective results
  • Enhanced ability to develop personalized treatment plans
  • Healthcare savings


Steven Lin, MD, PhD

Associate Professor, Radiation Oncology
MD Anderson Cancer Center

Dr. Steven Lin received a Doctorate of Medicine and of Philosophy (MD-PhD) degree from the University of California, Irvine in 2004. Dr. Lin’s doctoral research was focused in Neuropharmacology under the guidance of Dr. Olivier Civellii, Professor of Neuropharmacology at the UCI College of Medicine. After finishing his dissertation work, Dr. Lin performed a post-doctoral fellowship in neuropharmacology at Neogene Technologies in Irvine, CA. Subsequently, Dr. Lin completed a Clinical Internship in Internal Medicine at Loma Linda University Medical Center, Loma Linda, CA, followed by a Clinical Residency in Radiation Oncology at The John Hopkins Hospital, Baltimore, MD.

Dr. Lin is a tenured Associate Professor and Physician-Scientist at MD Anderson Cancer Center with a primary research interest focused on translational research to enhance radiotherapy cure rates in thoracic cancers, particularly lung and esophageal cancers. A major roadblock to improving cure rates is our inability to improve outcomes beyond standard chemoradiation (CRT) approaches for locally advanced disease, which continues to have dismal survival outcomes in all cancer types, particularly thoracic cancers. One of his key research interests is to identify and develop predictive biomarkers for therapy responsiveness. This could come in the form of functional imaging or blood/tissue-based biomarkers.